Full-Time

National Corporate Account Director

Confirmed live in the last 24 hours

Corcept Therapeutics

Corcept Therapeutics

201-500 employees

Develops cortisol modulators for medical conditions

Biotechnology
Healthcare

Compensation Overview

$227k - $267.1kAnnually

Senior, Expert

Remote in USA

Category
Strategic Account Management
Sales & Account Management
Requirements
  • Experience in oncology specialty distribution, specialty pharmacy, community oncology GPO, and community oncology key account management
  • Extensive customer relationships and experience
  • Experience launching oral oncology therapies in the community oncology setting with a focus on driving results and meeting or exceeding objectives
  • Demonstrated ability to meet assigned objectives and drive results within agreed upon timelines
  • Effective oral and written communication skills and ability to engage at all levels of the organization including C-Suite level relationships
  • Excellent negotiation skills with a focus on finding solutions to meet organizational goals
  • Collaborative work and communication style fostering cross-functional teamwork
  • Working knowledge of US healthcare policies and relevant legal, compliance, regulatory, and reporting requirements
  • Bachelor’s Degree; Master’s degree preferred
  • Strategic mindset and patient-centric approach to the business
  • Ability to thrive in a fast-paced, dynamic environment
  • 10+ years of pharmaceutical industry experience including current and/or previous oncology experience
  • 5+ years of related assigned account experience
  • Pharmaceutical field sales leadership experience preferred
Responsibilities
  • Execute the specialty distribution, community GPO, and key account strategies to ensure appropriate practice adoption and patient access
  • Negotiate specialty distribution (SDs) service agreements and related agreements, and maintain agreed upon service levels. Perform periodic business reviews
  • Negotiate service and data-sharing agreements with assigned oncology Specialty Pharmacy partners to meet brand objectives
  • Coordinate periodic business reviews
  • Identify and manage the execution of educational opportunities with assigned community oncology GPOs (ie Unity, Onmark, ION, etc.) to inform GPO members and support patient access through GPO meeting sponsorships opportunities and in-practice programs
  • Negotiate and manage GPO contracts to support patient access through in-practice dispensing
  • Manage relationships with community oncology key accounts with in-practice dispensing capabilities and centralized decision making
  • Collaborate with the field sales team to ensure coordination in key community oncology accounts
  • Support partnerships with assigned oncology trade organizations such as COA and NCODA
  • Analyze product volume, trends, and growth, for assigned accounts. Develop and implement account level business plans and work with market access marketing to develop segment strategies and resources
  • Monitor and ensure that partners adhere to contract terms

Corcept Therapeutics focuses on developing treatments that regulate cortisol levels in the body, which is important for managing stress, metabolism, and immune functions. Their main product, Korlym, is the first FDA-approved treatment for Cushing's syndrome, a condition caused by excessive cortisol. The company has discovered over 1,000 selective cortisol modulators and aims to expand its offerings with new treatments in development. Unlike many competitors, Corcept emphasizes both research and patient education, providing resources to healthcare professionals and patients to improve understanding and care for cortisol-related conditions. The goal of Corcept is to lead in cortisol modulation therapies and enhance patient outcomes for those suffering from related disorders.

Company Stage

IPO

Total Funding

$39.7M

Headquarters

Menlo Park, California

Founded

1998

Growth & Insights
Headcount

6 month growth

23%

1 year growth

31%

2 year growth

49%
Simplify Jobs

Simplify's Take

What believers are saying

  • Growing interest in cortisol therapies due to stress-related health awareness boosts market potential.
  • Advancements in personalized medicine could enhance the effectiveness of Corcept's treatments.
  • Increased investments in biopharmaceuticals focusing on niche markets support Corcept's growth.

What critics are saying

  • Teva's antitrust lawsuit could lead to legal expenses and market share loss.
  • Strategic shift towards oncology may divert resources from core cortisol focus.
  • Recent stock offering may dilute shareholder value, indicating potential financial challenges.

What makes Corcept Therapeutics unique

  • Corcept specializes in cortisol modulation, a niche market with few competitors.
  • Korlym is the first FDA-approved treatment for hypercortisolism in Cushing's syndrome.
  • Corcept has discovered over 1,000 selective cortisol modulators, showcasing strong R&D capabilities.

Help us improve and share your feedback! Did you find this helpful?